

Table 1. Three year follow up results from Checkmate 649 for all patients and for patients with PD-L1 CPS \geq 5

Population	Nivolumab + chemotherapy	Chemotherapy alone	HR (95% CI)
Median overall survival (months)			
Overall (n = 1581)	13.7	11.6	0.79 (0.71 to 0.88)
PD-L1 CPS \geq 5 (n = 955)	14.4	11.1	0.70 (0.61 to 0.81)
Median progression free survival (months)			
Overall (n = 1581)	7.7	6.9	0.79 (0.71 to 0.89)
PD-L1 CPS \geq 5 (n = 955)	8.3	6.1	0.70 (0.60 to 0.81)
Objective response rate (%)			
Overall (n = 1209)	58	46	NR
PD-L1 CPS \geq 5 (n = 768)	60	45	NR
CI: confidence interval; HR: hazard ratio; NR: not reached			